![]() ![]() The Company's products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a) BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders. The ratio of debt to operating expenses for SecureWorks Corp is higher than. Price to trailing twelve month operating cash flow for SCWX is currently 42.29, higher than 87.73 of US stocks with positive operating cash flow. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. SCWXs went public 5.58 years ago, making it older than just 21.32 of listed US stocks were tracking. The Company focuses on biosimilars, which are biologic drugs. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |